The Business Times
business-time-50

Lonza in joint venture to develop biotherapeutic products

Ng Ren Jye

Published Wed, Apr 3, 2019 · 09:50 PM

Singapore

SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.

lonza

TRENDING NOW

Related issues that LTA is also seeking feedback on are over COE renewals and Category E.

LTA proposes combining car COE categories, adding rebate-surcharge system

StarHub says the acquisition will allow greater scale to be directed towards sustained network investment, service innovation and customer experience. 

StarHub to acquire MyRepublic’s mobile business amid ongoing telco consolidation

All three local banks ended lower, with OCBC declining 4.3% or S$1.30 to S$29.

DBS, OCBC, UOB rout lops billions off STI as inflation, rate concerns spook investors

From shy teenager to outspoken philanthropist, Chloe Tong has come a long way.

Grab CEO’s wife Chloe Tong on life with Anthony Tan and finding her purpose

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More